Metformin and Nightly Fasting in Women With Early Breast Cancer

Major Program
Cancer Prevention Clinical Trials Network
Research Group
Breast and Gynecologic Cancer
National Cancer Institute (NCI)
Not yet recruiting ID
For more information, see NCT05023967
This phase IIb trial studies the combined effect of prolonged nightly fasting and metformin
hydrochloride extended release in decreasing breast tumor cell proliferation and other
biomarkers of breast cancer. Preventing invasive breast cancer or DCIS. Metformin is widely
used to treat type II diabetes and is associated with a decreased risk of cancer and death in
diabetic individuals. Intermittent fasting may protect cancer patients from the toxic effects
of chemotherapy agents without causing chronic weight loss. The combination of intermittent
fasting and metformin may reduce breast cancer growth and may be used in women at risk for
breast cancer or other cancers associated with being overweight.
Biospecimen Collection, Extended Release Metformin Hydrochloride, Monitoring, Nutritional Assessment, Short-Term Fasting
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Andrea De Censi, Powel H. Brown, Bernardo Bonanni

See list of participating sites